GSK GSK3.22%increase; green up pointing triangle agreed to pay more than $2 billion to settle almost all remaining liability cases in the U.S. over allegations its discontinued heartburn medicine ...

We recently published an article titled Jim Cramer on Super Micro Computer and Other Stocks. In this article, we are going to ...

GSK has agreed to pay up to $2.2 billion to resolve approximately 80,000 lawsuits brought by users of Zantac who claimed the heartburn drug caused their cancer. The agreement frees the British ...

GSK has shifted towards a global marketing model influenced by a Netflix-style approach that aims to match content to the person receiving it. Richard Staines heard about this new strategy at the ...

What is the current and next Wuthering Waves banner? Otherwise known as Convenes, WuWa banners run on a three-week rotation, which doesn’t give you much time to decide which characters to pull ...

Sept 18 (Reuters) - British drugmaker GSK (GSK.L), opens new tab said on Wednesday it had agreed to settle two lawsuits in California that claimed its discontinued heartburn drug Zantac caused cancer.

After an initial defeat against the biggest barrier to mRNA flu vaccines—namely, B strains of influenza—GSK has returned with a reformulated candidate that has delivered the goods in the all ...

iTeos Therapeutics (NASDAQ:ITOS) announced Saturday that its experimental cancer doublet therapy developed with GSK (NYSE:GSK) outperformed the British drugmaker’s FDA-approved anti-PD-1 therapy ...

GSK has demonstrated robust sales growth, with a 13% increase to GBP 7.9 billion and a core operating profit up by 21% to GBP 2.5 billion, as noted by CEO Emma Walmsley in the latest earnings call.

However, the earlier flops shook TIGIT players, with GSK and iTeos assessing “how best to proceed with additional clinical development” of their rival asset after a phase 3 Roche flop in 2022 ...

BARCELONA, Spain — A targeted immunotherapy being developed by the biotech iTeos Therapeutics and GSK delivered promising response rates in patients with a type of lung cancer, propelling the ...

In a rough day for PARP inhibitors in ovarian cancer, GSK’s Zejula didn’t deliver a life extension benefit in the final analysis of a phase 3 trial. Another study showed that pharma&’s ...